Krista Davis Sells 2,084 Shares of ANI Pharmaceuticals (NASDAQ:ANIP) Stock

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) SVP Krista Davis sold 2,084 shares of ANI Pharmaceuticals stock in a transaction that occurred on Thursday, February 19th. The stock was sold at an average price of $77.53, for a total value of $161,572.52. Following the transaction, the senior vice president directly owned 50,993 shares in the company, valued at approximately $3,953,487.29. This trade represents a 3.93% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Krista Davis also recently made the following trade(s):

• On Friday, February 20th, Krista Davis sold 1,730 shares of ANI Pharmaceuticals stock. The shares were sold at an average price of $77.99, for a total value of $134,922.70.
• On Thursday, December 18th, Krista Davis sold 1,622 shares of ANI Pharmaceuticals stock. The shares were sold at an average price of $82.40, for a total transaction of $133,652.80.

ANI Pharmaceuticals Stock Up 2.1%

ANIP stock opened at $76.70 on Wednesday. The company has a market cap of $1.72 billion, a price-to-earnings ratio of 47.06 and a beta of 0.50. The company has a fifty day moving average price of $80.60 and a 200 day moving average price of $86.60. The company has a debt-to-equity ratio of 1.20, a current ratio of 2.58 and a quick ratio of 2.04. ANI Pharmaceuticals, Inc. has a 12 month low of $54.10 and a 12 month high of $99.50.

Trending Headlines about ANI Pharmaceuticals

Here are the key news stories impacting ANI Pharmaceuticals this week:

• Positive Sentiment: Management will present at three major investor conferences in early March (Raymond James, Leerink Partners, Barclays); live and archived webcasts available on the company site for 90 days — helps visibility and investor access to management’s growth story. GlobeNewswire Release
• Positive Sentiment: Analyst coverage remains constructive: recent buy/overweight ratings and several price targets well above the current price (median/consensus targets indicate upside), supporting investor confidence. MarketBeat Analyst Notes
• Neutral Sentiment: Street preview pieces highlight expected strength in Cortrophin Gel and rare-disease momentum ahead of Q4 results — this implies potential upside but also flags generic pressure risks; outcome depends on reported numbers. Zacks Preview
• Neutral Sentiment: Recorded short-interest data in the feed shows zero shares / anomalous NaN change and a 0.0 days-to-cover metric — appears to be a data glitch and is unlikely to be an actionable signal by itself.
• Neutral Sentiment: Institutional/hedge-fund activity is mixed: some large reallocations reported (both adds and sizable removals across different funds in the latest quarter), so ownership trends are shifting but not uniformly bullish or bearish. Quiver Quant Summary
• Negative Sentiment: Several insiders (including SVP Krista Davis and Head of Rare Disease Christopher Mutz) disclosed market sales of ANIP shares in recent sessions; repeated insider selling can be perceived as a modest negative signal for near-term sentiment. InsiderTrades Filing

Wall Street Analyst Weigh In

Several equities analysts recently issued reports on ANIP shares. Zacks Research cut ANI Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, January 6th. Barclays began coverage on ANI Pharmaceuticals in a research note on Tuesday, December 9th. They issued an “overweight” rating and a $100.00 target price on the stock. Guggenheim upped their price target on ANI Pharmaceuticals from $115.00 to $124.00 and gave the stock a “buy” rating in a research note on Friday, January 16th. Finally, Weiss Ratings reaffirmed a “hold (c+)” rating on shares of ANI Pharmaceuticals in a report on Monday, December 29th. Six research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $103.43.

Hedge Funds Weigh In On ANI Pharmaceuticals

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. Hantz Financial Services Inc. lifted its holdings in shares of ANI Pharmaceuticals by 202.6% in the 3rd quarter. Hantz Financial Services Inc. now owns 354 shares of the specialty pharmaceutical company’s stock valued at $32,000 after buying an additional 237 shares during the period. Advisors Asset Management Inc. acquired a new stake in ANI Pharmaceuticals in the first quarter valued at $28,000. Caitong International Asset Management Co. Ltd lifted its holdings in ANI Pharmaceuticals by 4,636.4% in the second quarter. Caitong International Asset Management Co. Ltd now owns 521 shares of the specialty pharmaceutical company’s stock valued at $34,000 after acquiring an additional 510 shares during the period. Newbridge Financial Services Group Inc. boosted its position in shares of ANI Pharmaceuticals by 200.0% during the 2nd quarter. Newbridge Financial Services Group Inc. now owns 600 shares of the specialty pharmaceutical company’s stock worth $39,000 after purchasing an additional 400 shares in the last quarter. Finally, Kemnay Advisory Services Inc. acquired a new position in shares of ANI Pharmaceuticals during the 4th quarter worth $48,000. Institutional investors and hedge funds own 76.05% of the company’s stock.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc is a United States–based specialty pharmaceutical company focused on the development, manufacturing and commercialization of generic and branded prescription drugs. The company operates as an end-to-end provider, offering services that range from active pharmaceutical ingredient (API) production and formulation development to finished dosage form manufacturing and packaging.

ANI’s product portfolio encompasses injectable and oral therapies across several therapeutic areas, including endocrinology, oncology, pain management and respiratory care.